Trial Profile
Safety interm of risk factors of nausea or anorexia in patients with idiopathic pulmonary fibrosis treated with nintedanib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jul 2018
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- 06 Jul 2018 New trial record
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society